查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1497656

心臟 POC 測試市場：按產品類型、生物標記類型和最終用戶 - 2024-2030 年全球預測

Cardiac Point of Care Testing Market by Product (Analyzers, Kits & Assays, Software & Services), Biomarker Type (Cardiac Troponins, CK-MB Fraction, D-Dimer), End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年心臟POC檢測市場規模為83.1億美元，2024年達93.8億美元，預計2030年將達到197.4億美元，複合年成長率為13.14%。

心臟 POC 測試是指對心臟病患者進行床邊或患者附近測試，有助於即時做出臨床決策。這種形式的診斷測試是在傳統實驗室環境之外進行的，通常在患者護理時間和地點進行，例如急診室、診所、救護車服務和重症監護病房。心臟 POC 測試的主要目的是獲得快速測試結果，可用於評估患者的心臟狀態，以便及時、知情的治療性介入。它通常用於檢測與心臟事件相關的生物標記物，例如肌紅蛋白、同型半胱氨酸和 Hs C 反應蛋白 (CRP)。在快速發展的醫療保健領域，由於對快速、準確的心血管診斷的需求不斷成長，心臟照護端 (POC) 測試市場正在蓬勃發展。該市場的定義是設計、製造和銷售易於使用的診斷設備和相應的反應劑，以促進現場心血管健康評估。這些設備可用於急診環境，為包括醫院、門診診所和家庭醫療保健在內的各種客戶提供服務。心血管疾病在人群中的盛行率不斷上升、技術進步有望提高診斷可靠性以及全球醫療保健投資的增加，推動了心臟 POC 測試的普及。然而，嚴格的法律規範、對診斷準確性的擔憂以及新興市場的財務限制等障礙正在阻礙全球心臟 POC 市場的擴張。心臟 POC 測試技術的改進和穩定發展，包括提高測試能力的設備和生物標記，為市場上的供應商提供了充滿希望的機會。

主要市場統計
基準年[2023] 83.1億美元
預測年份 [2024] 93.8億美元
預測年份 [2030] 197.4億美元
複合年成長率（%） 13.14%

區域洞察

在美洲，由於心血管疾病的流行、醫療成本的增加以及強大的醫療基礎設施的存在，心臟 POC 測試市場繼續穩定成長。此外，最尖端科技的採用、積極的政府舉措以及由於主要市場參與者的存在而提供的廣泛產品正在推動成長。 EMEA（歐洲、中東和非洲）地區的市場格局充滿活力，歐洲市場受益於有利的政府政策、大量老年人口以及旨在減輕心血管疾病負擔的舉措。由於中東國家醫療保健投資增加以及非洲心臟健康意識不斷增強，中東和非洲市場不斷成長。亞太地區是心臟 POC 檢測前景看好的市場，與美洲和歐洲、中東和非洲相比，預計成長率最高。這是由中國和印度等國家龐大的人口基數、快速發展的醫療基礎設施以及不斷成長的醫療支出所推動的。此外，包括心臟病文明病在該地區呈上升趨勢，進一步增加了對快速高效診斷方法的需求。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在心臟 POC 測試市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對心臟 POC 測試市場中供應商的現狀進行深入而詳細的評估。對供應商貢獻的徹底比較和分析可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外，該分析還提供了對該行業競爭性質的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在心臟 POC 測試市場中的地位進行全面評估，使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人群心血管疾病發生率增加
      • 政府對POC測試的積極推動介紹
      • 改善世界各地經濟體的醫療保健支出
    • 抑制因素
      • 心臟 POC 測試中使用的材料和組件的成本變化
    • 機會
      • 心臟 POC 測試的改進和持續進步
      • 新生物標記物開發進展以提高檢測能力
    • 任務
      • 心臟 POC 測試的操作和技術複雜性
  • 市場區隔分析
    • 產品：診所對多重檢測的需求增加
    • 生物標記類型：用於早期心臟檢測的心臟型脂肪酸結合蛋白質（H-FABP）和缺血修飾白蛋白（IMA）的需求不斷增加
    • 最終用戶：在具有大樣本量的複雜系統的診斷實驗室中增加使用心臟 POC 測試
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章心臟 POC 測試市場：依產品

  • 分析儀
  • 套件和檢測
  • 軟體和服務

第7章按生物標記類型分類的心臟 POC 測試市場

  • 心肌肌鈣蛋白
  • CK-MB分數
  • D-二聚體
  • 心型脂肪酸結合蛋白質（H-FABP）
  • 同型半胱氨酸
  • hs C 反應蛋白 (CRP)
  • 缺血修飾白蛋白 (IMA)
  • 肌紅蛋白
  • 利尿鈉胜肽(NP)
  • sCD40L

第 8 章 心臟 POC 測試市場：依最終用戶分類

  • 診斷實驗室
  • 醫院/診所
  • 研究/學術機構

第9章 美洲心臟POC測試市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太心臟POC測試市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲心臟POC測試市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Hipro照護現場診斷在印度推出
    • Jana Care 與羅氏合作開發和分銷血液檢測平台，以改善慢性腎臟病和心臟病患者的遠距護理
    • Cipla 擴大診斷產品組合併推出就地檢驗設備
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-3F5063247F53

[183 Pages Report] The Cardiac Point of Care Testing Market size was estimated at USD 8.31 billion in 2023 and expected to reach USD 9.38 billion in 2024, at a CAGR 13.14% to reach USD 19.74 billion by 2030.

Cardiac point of care testing refers to the bedside or near-patient testing of cardiac patients that facilitates immediate clinical decision-making. This form of diagnostic testing is performed outside of traditional laboratory environments, typically at the time and place of patient care, such as in emergency departments, clinics, ambulance services, or critical care units. The primary goal of cardiac point of care testing is to obtain rapid test results that can be used to assess the condition of a patient's heart, enabling timely and informed treatment interventions. It is often utilized for the detection of biomarkers associated with cardiac events, including myoglobin, homocysteine, and hs C-reactive protein (CRP). In the rapidly advancing domain of healthcare, the cardiac point of care (POC) testing market is gaining momentum, driven by the escalating need for swift and precise cardiovascular diagnostics. This market is defined by the engineering, manufacturing, and commerce of user-friendly diagnostic instruments and their corresponding reactive agents that facilitate on-site cardiovascular health assessments. These devices, instrumental within acute medical scenarios, cater to a diverse clientele across hospitals, outpatient clinics, and home healthcare. The proliferation of cardiac point of care testing is driven by increasing incidences of cardiovascular diseases among the population, technological strides that promise enhanced diagnostic veracity, and rising global healthcare investment. Despite obstacles such as stringent regulatory frameworks, concerns over diagnostic accuracy, and financial limitations in developing health ecosystems hinder the scope of the global cardiac point of care market. Improvements and robust advancements in cardiac POC testing technologies, including devices and biomarkers to improve testing capabilities, portray promising opportunities for the market vendors.

KEY MARKET STATISTICS
Base Year [2023] USD 8.31 billion
Estimated Year [2024] USD 9.38 billion
Forecast Year [2030] USD 19.74 billion
CAGR (%) 13.14%

Regional Insights

In the Americas, the market for cardiac point of care testing continues to display robust growth, driven by the prevalence of cardiovascular diseases, rising healthcare expenditure, and the presence of robust healthcare infrastructure. Additionally, the growth is facilitated by the adoption of cutting-edge technologies, active government initiatives, and the availability of a wide range of products owing to the presence of significant market players. The EMEA region experiences a dynamic market landscape for cardiac point of care testing, where the European market benefits from favorable government policies, a high geriatric population, and an increasing number of initiatives aimed at lowering the burden of cardiovascular diseases. The Middle East and Africa showcase a growing market due to rising healthcare investments in the Middle Eastern countries and the growing awareness of cardiac health in Africa. The APAC region represents a promising market for cardiac point of care testing, with expectations for the highest growth rate in comparison to the Americas and EMEA. This is attributed to the vast population base, rapidly developing healthcare infrastructure in countries including China and India, and an increase in healthcare spending. Additionally, the region is experiencing a rise in lifestyle-related diseases, including heart conditions, which further propels the demand for quick and efficient diagnostic methods.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Cardiac Point of Care Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing incidences of cardiovascular disorders among the population
      • Favorable government initiatives for the introduction of POC testing
      • Improving healthcare expenditure across economies worldwide
    • Market Restraints
      • Fluctuating cost of materials and components used in cardiac POC testing
    • Market Opportunities
      • Improvements and continuous advancements in cardiac POC testing
      • Advances in the development of new biomarkers to improve testing capabilities
    • Market Challenges
      • Operational and technical complexities in cardiac POC testing
  • Market Segmentation Analysis
    • Product: Increasing demand for multiplex assays across clinics
    • Biomarker Type: Increasing demand for heart-type fatty acid-binding protein (H-FABP) and ischemia-modified albumin (IMA) for early cardiac detection
    • End-user: Rising usage of cardiac POC testing in diagnostic laboratories for complex systems with high sample capacities
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cardiac Point of Care Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cardiac Point of Care Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Hipro Point-of-Care Diagnostics Launched in India

Analyzers are instruments used to detect the presence and concentration of cardiac biomarkers, such as troponin, B-type natriuretic peptide (BNP), and other substances indicative of cardiovascular diseases. The need for analyzers arises when immediate results are critical for diagnosing and managing cardiac conditions, particularly in emergency settings. [Published On: 2023-04-22]

Jana Care to Enter Collaboration with Roche to Develop and Distribute Blood Testing Platform to Improve Remote Care for Patients With Chronic Kidney and Heart Disease

Jana Care Inc. partnered with Roche Diagnostics, to develop and distribute a blood testing platform to enhance remote care for patients with chronic kidney and heart disease. The initial phase of this collaborative effort spotlights the management and surveillance of chronic conditions, specifically chronic kidney disease and heart failure. Aimed at bridging gaps created by geographical and socio-economic barriers, this platform is poised to enhance early detection and consistent monitoring, thereby optimizing the management and mitigation of disease progression. [Published On: 2023-01-30]

Cipla expands diagnostics portfolio, launches point-of-care testing device

Cipla Limited has broadened its position in diagnostics with the rollout of Cippoint, a cutting-edge point-of-care testing device. This versatile innovation is engineered to facilitate an expansive array of diagnostic evaluations encompassing cardiac markers, making it particularly vital for rapid cardiac care. Additionally, it serves a multifunctional purpose by enabling the testing for diabetes, a variety of infectious diseases, fertility concerns, thyroid irregularities, inflammation, metabolic markers, and coagulation profiles. [Published On: 2023-01-18]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cardiac Point of Care Testing Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Point of Care Testing Market, highlighting leading vendors and their innovative profiles. These include Abaxis, Inc. by Zoetis Inc, Abbott Laboratories, ACON Laboratories, Inc., Beckman Coulter, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Cardiac Insight Inc., CardioGenics Holdings Inc., Chembio Diagnostic Systems, Inc. by Biosynex, EKF Diagnostics, F. Hoffmann-La Roche Ltd., Fujirebio, Horiba, Ltd., I-Sens Inc., LifeSign LLC, Nexus Dx, Inc. by Sinocare, Nova Biomedical, PTS Diagnostics by Danaher Corporation, Quidel Corporation, Radiometer Medical ApS, Randox Laboratories Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trividia Health, Inc..

Market Segmentation & Coverage

This research report categorizes the Cardiac Point of Care Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Analyzers
    • Kits & Assays
    • Software & Services
  • Biomarker Type
    • Cardiac Troponins
    • CK-MB Fraction
    • D-Dimer
    • Heart-Type Fatty Acid-Binding Protein (H-FABP)
    • Homocysteine
    • hs C-reactive Protein (CRP)
    • Ischemia-Modified Albumin (IMA)
    • Myoglobin
    • Natriuretic Peptides (NPs)
      • Atrial Natriuretic Peptide (ANP)
      • B-type Natriuretic Peptide (BNP)
      • N-terminal proBNP (NT-proBNP)
    • sCD40L
  • End-User
    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Research & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of cardiovascular disorders among the population
      • 5.1.1.2. Favorable government initiatives for the introduction of POC testing
      • 5.1.1.3. Improving healthcare expenditure across economies worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. Fluctuating cost of materials and components used in cardiac POC testing
    • 5.1.3. Opportunities
      • 5.1.3.1. Improvements and continuous advancements in cardiac POC testing
      • 5.1.3.2. Advances in the development of new biomarkers to improve testing capabilities
    • 5.1.4. Challenges
      • 5.1.4.1. Operational and technical complexities in cardiac POC testing
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing demand for multiplex assays across clinics
    • 5.2.2. Biomarker Type: Increasing demand for heart-type fatty acid-binding protein (H-FABP) and ischemia-modified albumin (IMA) for early cardiac detection
    • 5.2.3. End-user: Rising usage of cardiac POC testing in diagnostic laboratories for complex systems with high sample capacities
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Cardiac Point of Care Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Analyzers
  • 6.3. Kits & Assays
  • 6.4. Software & Services

7. Cardiac Point of Care Testing Market, by Biomarker Type

  • 7.1. Introduction
  • 7.2. Cardiac Troponins
  • 7.3. CK-MB Fraction
  • 7.4. D-Dimer
  • 7.5. Heart-Type Fatty Acid-Binding Protein (H-FABP)
  • 7.6. Homocysteine
  • 7.7. hs C-reactive Protein (CRP)
  • 7.8. Ischemia-Modified Albumin (IMA)
  • 7.9. Myoglobin
  • 7.10. Natriuretic Peptides (NPs)
  • 7.11. sCD40L

8. Cardiac Point of Care Testing Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals & Clinics
  • 8.4. Research & Academic Institutes

9. Americas Cardiac Point of Care Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cardiac Point of Care Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cardiac Point of Care Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Hipro Point-of-Care Diagnostics Launched in India
    • 12.3.2. Jana Care to Enter Collaboration with Roche to Develop and Distribute Blood Testing Platform to Improve Remote Care for Patients With Chronic Kidney and Heart Disease
    • 12.3.3. Cipla expands diagnostics portfolio, launches point-of-care testing device
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CARDIAC POINT OF CARE TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. CARDIAC POINT OF CARE TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CARDIAC POINT OF CARE TESTING MARKET DYNAMICS
  • FIGURE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. CARDIAC POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. CARDIAC POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CARDIAC POINT OF CARE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ANALYZERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CARDIAC TROPONINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CARDIAC TROPONINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK-MB FRACTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK-MB FRACTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY D-DIMER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY D-DIMER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART-TYPE FATTY ACID-BINDING PROTEIN (H-FABP), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART-TYPE FATTY ACID-BINDING PROTEIN (H-FABP), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOMOCYSTEINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOMOCYSTEINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HS C-REACTIVE PROTEIN (CRP), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HS C-REACTIVE PROTEIN (CRP), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ISCHEMIA-MODIFIED ALBUMIN (IMA), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ISCHEMIA-MODIFIED ALBUMIN (IMA), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ATRIAL NATRIURETIC PEPTIDE (ANP), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ATRIAL NATRIURETIC PEPTIDE (ANP), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE (BNP), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE (BNP), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY N-TERMINAL PROBNP (NT-PROBNP), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY N-TERMINAL PROBNP (NT-PROBNP), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SCD40L, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SCD40L, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 84. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 85. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 116. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 120. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 122. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 123. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 124. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 125. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 128. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 129. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 130. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 131. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 132. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 133. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 136. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 137. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 138. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 139. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 140. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 141. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 144. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 145. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 146. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 147. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 148. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 149. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 152. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 153. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 154. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 155. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 156. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 157. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 160. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 161. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 164. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 168. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 170. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 171. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 172. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 173. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 176. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 177. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 178. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 180. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 184. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 188. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 189. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 192. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 193. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 194. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 195. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 196. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 197. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 200. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 201. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 204. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 205. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 208. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 209. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 210. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 221. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 222. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 223. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 226. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 227. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 228. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 229. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 230. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 231. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 234. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 235. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 238. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 239. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 242. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 243. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 244. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 245. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 246. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 247. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 250. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 251. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 254. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 255. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 258. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 259. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 260. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 261. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 262. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 263. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 266. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 267. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 268. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 269. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 270. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 271. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 274. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 275. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 276. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 278. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 282. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 283. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 286. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 287. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 290. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 291. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 292. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 293. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 294. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 295. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 298. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 299. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 300. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 301. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 302. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 303. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 306. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (U